Related Experiment Video
Updated: Aug 13, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
Cardiac Contractility Modulation: Implications in Heart Failure, a Current Review
Alexander L Wallner1, Salvatore Savona1, Rami Kahwash1
1Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Abstract:
Cardiac contractility modulation (CCM) is a novel therapeutic approach for heart failure patients, which utilizes nonexcitatory electrical myocardial stimulation in the absolute refractory period of the cardiac cycle. This stimulation has been shown to increase contractility, leading to improved heart failure symptoms, functional status, and quality of life. CCM is FDA approved for heart failure patients with an LVEF between 25% and 45% who remained symptomatic despite optimal medical therapy and not candidate of cardiac resynchronization therapy. CCM offers expanded treatment options for heart failure patients who have continued symptoms while on optimal medical therapy.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure V: Medical Management
Pathophysiology of Heart Failure
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy II: Dilated Cardiomyopathy
